ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

EVG Evgen Pharma Plc

0.875
0.00 (0.00%)
Last Updated: 08:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.875 0.85 0.90 0.875 0.875 0.875 0.00 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 422k -4.04M -0.0147 -0.59 2.39M

Evgen Pharma PLC SFX-01 data published in Peer Reviewed Journal

02/08/2017 1:00pm

RNS Non-Regulatory


TIDMEVG

Evgen Pharma PLC

02 August 2017

 
 For immediate release   2 August 2017 
 
 

RNS Reach

Evgen Pharma plc

("Evgen Pharma" or "the Company")

SFX-01 data published in Peer Reviewed Journal

Evgen Pharma's SFX-01 protects against gait anomalies and modifies bone microarchitecture in the spontaneous STR/Ort model of osteoarthritis

Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, is pleased to announce the publication in a peer reviewed scientific journal of its lead product, SFX-01 and its protective effects against osteoarthritis.

The paper, "Stable sulforaphane protects against gait anomalies and modifies bone microarchitecture in the spontaneous STR/Ort model of osteoarthritis", has been published in the journal Bone and describes the work undertaken by researchers to see how SFX-01 modifies gait, bone architecture and slows or reverses articular cartilage destruction in a spontaneous osteoarthritis model in mice.

The paper can be viewed at: http://www.thebonejournal.com/article/S8756-3282(17)30263-6/fulltext?cc=y= (Behzad Javaheri et al; Stable sulforaphane protects against gait anomalies and modifies bone microarchitecture in the spontaneous STR/Ort model of osteoarthritis, Bone, 2017).

This follows the news in the AGM Statement announced on 26 July 2017, that Evgen, together with the RVC, University of London, has secured grant funding to continue its collaboration to build on this, now published, preclinical data demonstrating the potential of SFX-01 as a treatment for osteoarthritis.

Enquiries:

 
 Evgen Pharma plc                          c/o +44 (0) 20 7466 
  Dr Stephen Franklin, CEO                                5000 
  Richard Moulson, CFO 
  www.evgen.com 
 
 Buchanan 
  Mark Court, Sophie Cowles, Stephanie         +44 (0) 20 7466 
  Watson                                                  5000 
 
 Northland Capital Partners Limited 
  Matthew Johnson, Gerry Beaney, 
  Margarita Mitropoulou (Corporate 
  Finance) 
  John Howes, Rob Rees (Corporate              +44 (0) 20 3861 
  Broking)                                                6625 
 
 

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Evgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com

For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAOKBDPDBKDDFK

(END) Dow Jones Newswires

August 02, 2017 08:00 ET (12:00 GMT)

1 Year Evgen Pharma Chart

1 Year Evgen Pharma Chart

1 Month Evgen Pharma Chart

1 Month Evgen Pharma Chart

Your Recent History

Delayed Upgrade Clock